Browse studies
Find your next paid study
40 recruiting studies matching your filters
Phase 2
Phase II Study of Hyper-CVAD Plus Nelarabine in Previously Untreated T-ALL and Lymphoblastic Lymphoma
This phase II trial studies the side effects and how well combination chemotherapy and nelarabine work in treating patients with T-cell acute lymphoblastic leu…
T Acute Lymphoblastic LeukemiaT Lymphoblastic Lymphoma
Estimated
~$10 – $6,250
M.D. Anderson Cancer CenterNCT00501826
Phase 2
Phase II Study of Dose-Adjusted EPOCH ± Rituximab + Ponatinib for Adults With Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma
This phase II trial tests the effect of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) with or without rituxima…
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1Lymphoblastic Lymphoma
Estimated
~$10 – $6,250
University of WashingtonNCT07224100
Observational
A Randomized Phase II Trial of Standard-of-Care Reduced-Intensity Conditioning (RIC) With 200 Versus 400 cGy of Total Body Irradiation (TBI) in Patients With Acute Leukemia Undergoing First Allogeneic Blood or Marrow Transplantation (BMT)
This is a randomized phase II trial of standard-of-care reduced-intensity conditioning (RIC) with 200 versus 400 cGy of total body irradiation (TBI) in patient…
Acute LeukemiaAcute Lymphoblastic Lymphoma
Estimated
~$10 – $6,250
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT06803745
Phase 1
A Phase I Study of Tagraxofusp With or Without Chemotherapy in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Tagraxofusp is a protein-drug conjugate consisting of a diphtheria toxin redirected to target CD123 has been approved for treatment in pediatric and adult pati…
Hematologic MalignancyAMLALL+8 more
Estimated
~$10 – $7,500
Therapeutic Advances in Childhood Leukemia ConsortiumNCT05476770